Room bioaerosol efficacy studies measure how room-scale and in-duct devices reduce airborne microbial concentrations over time. ARE Labs uses controlled chambers or duct sections, nebulized organism surrogates, viable impingers, filter collection, and culture, qPCR, or droplet digital PCR (ddPCR) endpoints. The resulting data support ISO 17025 records and performance claims aligned with ASHRAE 241 or AHAM AC-1:
- Room air cleaner benchmarking under ASHRAE 241 context, using chamber release, viable sampling, and log reduction curves for portable or fixed air-treatment devices.
- UVGI design verification for room or duct systems, using ISO 17025 records, UV dose logging, airflow data, and viable recovery to compare operating modes.
- In-duct HVAC add-on evaluation aligned to ASTM E3273 or ISO 16000-36, using defined flow, organism recovery, and device-off controls for reduction claims.
- EPA OPPT claim support for antimicrobial or air-treatment products, using organism selection, recovery validation, and replicate chamber runs matched to the claim language.
- AHAM AC-1 adjacent air cleaner studies under ISO 17025 records, using controlled bioaerosol challenges and device-off decay baselines to translate particle CADR concepts into microbial reduction data.
Use room bioaerosol efficacy testing when a decision depends on measured microbial reduction under defined airflow, mixing, RH, and temperature conditions. Before testing begins, the study plan defines the organism panel, chamber or duct configuration, endpoints, and aligned standards.